Last reviewed · How we verify

NCT03582319

Clinical and Radiographic Evaluation of Biodentine Versus Formocresol

Completed NA Last updated 11 July 2018
What this trial tests

NA trial testing Biodentine in Pulp Disease, Dental in 43 participants. Completed in 22 February 2018.

Timeline
12 February 2017
Primary endpoint
20 January 2018
22 February 2018

Quick facts

Lead sponsorCairo University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment43
Start date12 February 2017
Primary completion20 January 2018
Estimated completion22 February 2018
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 4 to 6, any sex, with Pulp Disease, Dental. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of the study: To compare Formocresol and Biodentine clinically and radiographically when used for pulpotomy of primary molars Study Design : A randomized control clinical trial (split mouth and double blind) was conducted on 43 (4-6 years-old) children with decayed vital mandibular primary molars which were treated by pulpotomy using both medicaments . All treated teeth were followed for one year (at 3, 6, 9 and 12 months clinically and at 6 and 9 radiographically).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Biodentine

Trials testing the same drug.

Other recruiting trials for Pulp Disease, Dental

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03582319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing